tbuckley/cabot-search huggingface dataset:
Book Listings
Journal: Annals of Internal Medicine (2001)

Book Listings6 February 2001Book ListingsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-3-200102060-00002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail CardiologyBasic Electrocardiography in Ten DaysDR Ferry. 266 pages. New York: McGraw-Hill; 2001. $40.00. ISBN 0071352929. Order phone 800-262-4729.Cardiac Pacing and Defibrillation: A Clinical ApproachDL Hayes, MA Lloyd, and PA Friedman. 600 pages. Armonk, NY: Futura; 2000. $89.00. ISBN 087993462X. Order phone 800-877-8761.Cardiovascular Medicine2nd edition. JT Willerson and JN Cohn, eds. 2344 pages. Philadelphia: WB Saunders; 2000. $165.00. ISBN 0443070008. Order phone 800-545-2522.Dispersion of Ventricular Repolarization: State of the ArtSB Olsson, JP Amlie, and S Yuan, eds. 330 pages. Armonk, NY: Futura; 2000. $125.00. ISBN 0879934581. Order phone 800-877-8761.Handbook of Contrast Echocardiography: Left Ventricular Function and ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 6 February 2001Volume 134, Issue 3Page: B1KeywordsBurnsHealth information technologyPrevention, policy, and public health ePublished: 6 February 2001 Issue Published: 6 February 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Daily Dietary Fat and Total Food-Energy Intakes—NHANES III, Phase 1, 1988-91
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A 50-year-old woman with disabling spinal stenosis
Authors: S. R. Garfin
Journal: JAMA (1995)

<h3>Dr Delbanco:</h3> Miss W is a 50-year-old woman who has a long history of low back pain. Divorced, she lives in an apartment by herself and works as a medical technician in a community-based doctor's office. She is insured through a large not-for-profit managed care organization. At 4 years of age, Miss W fell off a horse, but she did not have subsequent problems until 18 years of age when she experienced low back pain. Since then, she has had intermittent pain and multiple therapeutic recommendations from chiropractors, orthopedists, and a neurosurgeon in addition to her primary care doctor. At times, she has been on prolonged periods of bed rest and has had to miss work. Approximately 8 years ago, Miss W developed symptoms of fibromyalgia with generalized pain focused on her knees, bunions, elbows, wrists, shoulders, and pelvic region. She has been treated with multiple nonsteroidal anti-inflammatory agents (NSAIDs),
Text-Book of Insanity Based on Clinical Observations, for Practitioners and Students of Medicine.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Spent Career of Robert Liston
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prospective randomised phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) with nonsquamous (Non SCC) histological type. NAVoTRIAL01: Final results.
Authors: Jaafar Bennouna, Libor Havel, Maciej Krzakowski, Jens Kollmeier, Radj Gervais, Eric Dansin, Monika Serke, Adolfo G. Favaretto, Manuel Cobo, Aleksandra Szczesna, Libero Ciuffreda, Jacek Jassem, Mario Nicolini, Rodryg Ramlau, Domenico Amoroso, Barbara Melotti, Teresa Almodovar, Nathalie Vaissiere, Marcello Riggi, Eng Huat Tan
Journal: Journal of Clinical Oncology (2013)

8043 Background: NVBo+P is considered as a standard treatment in M or LA NSCLC. The recent approval of Pem+P as front line chemotherapy (CT) for non SCC demonstrates that today, histology could become a “new guidance” to treat patients (pts). The importance of histological types was highlighted in a phase III trial (Scagliotti. JCO 2008). Moreover, the higher chemosensitivity of non SCC is recognised and reported with other chemotherapies (Ardizzoni. JNCI 2007). In GLOB 3 study, NVBo+P also showed better survival in adenocarcinoma (11.7m) than in SCC (8.9m) (Tan. Ann Oncol. 2009). This trial was set up to assess the efficacy of NVBo+P (Arm A) and Pem+P (Arm B) for pts with Non SCC histological type, evaluated in terms of Disease Control Rate (DCR) (SD+PR+CR). Methods: Pts were randomised to receive q3w NVBo 80 mg/m² D1D8 (60 at Cycle 1) + P 80 mg/m² D1 (Arm A) or Pem 500 mg/m² + P 75 mg/m² D1 (Arm B). After 4 cycles of combination, pts with DCR received single agent NVBo (Arm A) or PEM (Arm B) as maintenance until progression or toxicity. Pts were randomised on a 2/1 basis and stratified according to stage (IIIB - IV - relapse), non SCC confirmed by histology or cytology, gender, smoking status and centre. Results: From 11/09 to 02/11, 153 pts were randomised to Arm A (102 pts) or Arm B (51 pts). DCR after combination and maintenance was 75.0% (95% CI, 65.3 to 83.1) in Arm A and 76.5% (95% CI, 62.5 to 87.2) in Arm B. Median PFS was 4.2 (95% CI, 3.6 to 4.7) and 4.3 months (95% CI, 3.8 to 5.6) in Arm A and Arm B, respectively. Median OS was 10.2 months (95% CI, 7.8 to 11.9) and 10.8 months (95% CI, 7.0 to16.4) in Arm A and Arm B, respectively. During the combination period grade 3/4 neutropenia was 44.0% in Arm A and 18.3% in Arm B but febrile neutropenia was 2% in both arms; grade 3/4 thrombopenia was 0% and 6% in Arm A and Arm B, respectively. Conclusions: Even if the current results should be confirmed in a phase III study, the choice of a platinum-based doublet with oral vinorelbine as front-line chemotherapy could be a useful alternative in non SCC. Clinical trial information: 2009-012001-19.
5-HT Receptor Regulation of Neurotransmitter Release
Authors: K. B. Fink, M. Gothert
Journal: Pharmacological Reviews (2007)

Serotoninergic neurons in the central nervous system impinge on many other neurons and modulate their neurotransmitter release. This review focuses on 1) the function of presynaptic 5-hydroxytryptamine (5-HT) heteroreceptors on axon terminals of central cholinergic, dopaminergic, noradrenergic, or GABAergic neurons and 2) the role of GABAergic interneurons expressing 5-HT heteroreceptors in the regulation of acetylcholine, dopamine, or noradrenaline release. In vitro studies on slices or synaptosomes and in vivo microdialysis experiments have shown that 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>3</sub>, and/or 5-HT<sub>4</sub> heteroreceptors mediate this modulation. 5-HT<sub>1B</sub> receptors on neocortical cholinergic, striatal dopaminergic, or hippocampal GABAergic axon terminals are examples for release-inhibiting 5-HT heteroreceptors; 5-HT<sub>3</sub> receptors on hippocampal GABAergic or 5-HT<sub>4</sub> receptors on hippocampal cholinergic axon terminals are examples for release-facilitating 5-HT heteroreceptors. GABA released from GABAergic interneurons upon activation of facilitatory 5-HT receptors, e.g., 5-HT<sub>2A</sub> or 5-HT<sub>3</sub> receptors, mediates inhibition of the release of other neurotransmitters such as prefrontal neocortical dopamine or neocortical acetylcholine release, respectively. Conversely, attenuated GABA release in response to activation of inhibitory 5-HT heteroreceptors, e.g., 5-HT<sub>1A</sub> or 5-HT<sub>1B</sub> receptors on GABAergic interneurons is involved in paradoxical facilitation of hippocampal acetylcholine and striatal dopamine release, respectively. Such 5-HT heteroreceptors are considered potential targets for appropriate 5-HT receptor ligands which, by enhancing the release of a relevant neurotransmitter, can compensate for its hypothesized deficiency in distinct brain areas. Examples for such deficiencies are the impaired release of hippocampal or neocortical acetylcholine, striatal dopamine, and hippocampal or neocortical noradrenaline in disorders such as Alzheimer9s disease, Parkinson9s disease, and major depression, respectively.
Pediatric Memoir
Authors: Sara C. McIntire
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Computer Sharpens Scanning Results
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
National Institutes of Health—Applications for Research Grants
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article National Institutes of Health—Applications for Research Grants Get access JNCI: Journal of the National Cancer Institute, Volume 17, Issue 5, November 1956, Page 699, https://doi.org/10.1093/jnci/17.5.699-a Published: 01 November 1956
SHARP – SPORTS MENTAL HEALTH AWARENESS RESEARCH PROJECT: PREVALENCE AND RISK FACTORS OF DEPRESSIVE SYMPTOMS AND LIFE STRESS IN ELITE ATHLETES
Authors: Sarah Beable, Mark Fulcher, Bruce Hamilton, Arier Chun-Lee
Journal: British Journal of Sports Medicine (2017)

<h3>Background</h3> Depression is a significant health issue. Recent athlete studies suggest depression is of similar prevalence to the general population, with risk factors such as retirement, concussion, and severe injury reported. The prevalence and identifiable risk factors amongst elite New Zealand athletes is unknown with no previous research in this field. <h3>Objective</h3> To assess the prevalence of <i>self-reported symptoms of depression</i> and <i>daily life hassles</i> in elite New Zealand athletes. <h3>Design</h3> A cross-sectional prospective epidemiological study. <h3>Setting</h3> The online anonymous survey was administered during a 2-month period from May to July 2015. <h3>Patients (or Participants)</h3> All current NZ athletes&gt;18 years from funded sports invited. 210 started the questionnaire, with 187 completing all responses. Only complete responses analysed. <h3>Main Outcome Measurements</h3> Demographic and health history obtained. Symptoms of depression were measured by the Centre for Epidemiological Studies Depression Scale- Revised (CESD-R). Life stress measured by the Daily Hassles Questionnaire. <h3>Results</h3> 21% (n=39) reported symptoms of moderate depression. Of these 40% met the criteria for a Major Depressive Episode. Only 2 of the 39 athletes were currently taking an anti-depressant medication. Those contemplating retirement,and partaking in individual sport had significantly increased odds of experiencing depression with young age also associated. Reported life stressors were higher in females, individual sports, those in partial employment and in a centralized programme. <i>Troubling thoughts about their future</i>, and <i>concerns about meeting high standards</i> were the highest reported life stress. There was a significant correlation between higher level of life stress and experiencing depressive symptoms <h3>Conclusion</h3> This study supports that depressive symptoms are prevalent in elite New Zealand athletes. Multiple risk factors have been identified pertaining to symptoms of depression and life stressors. These concepts and variables warrant further exploration to enable appropriate screening and support for elite athletes.
A clinicopathologic study of primary mediastinal large B-cell lymphoma (MLBCL) at a single institution in Japan
Authors: N. Sekiguchi, J. Nishimoto, K. Tanimoto, Y. Ohnishi, T. Watanabe, Y. Kobayashi, H. Asamura, Y. Kagami, Y. Matsuno, K. Tobinai
Journal: Journal of Clinical Oncology (2004)

6686 Background: Numerous clinicopathologic studies of MLBCL have been reported from US and European countries; however, only a few case-series of at most 10 cases are available from Japan and other East Asian countries. Recent investigations revealed that the molecular signature of MLBCL differs from that of other types of diffuse large B-cell lymphoma and shares features with Hodgkin's lymphoma (HL). Considering the low incidence of HL in East Asia, the incidence and clinical features of MLBCL patients (pts) might be also different. To further clarify the clinicopathologic features of pts with MLBCL in Japan, we conducted a retrospective study. Methods: A total of 28 pts with MLBCL who were diagnosed and treated at our institution between 1982 and 2002 were analyzed. Results: The median age was 37 years (range, 18–80). Sixteen male pts showed a bimodal age distribution with one peak at 30–50 years of age and another peak in the 60s, whereas 12 female pts showed a single peak at 20–40 years. The median follow-up duration in all pts was 21 months and that in surviving pts was 35.7 months. Only 13 pts (46%) achieved complete response (CR) by initial treatments, mostly by CHOP-like regimens followed by radiotherapy. The estimated 3-year disease-free survival of the 13 pts who achieved CR was 66%; however, the estimated 3-year overall and failure-free survivals for all 28 pts were 32% and 33%, respectively. A multivariate analysis revealed that age ≥ 40 and PS > 1 were independent factors significantly associated with shortened survival. Conclusions: The clinicopathologic features of Japanese pts with MLBCL might differ from those in US and European countries, especially with respect to male/female ratio, age distribution and unfavorable clinical outcome. Further large-scale studies, including molecular diagnosis and new approaches to the optimal management, are warranted. No significant financial relationships to disclose.
In This Issue
Journal: Journal of Clinical Investigation (2011)

Kidney maintains its integrity with Arhgap24Focal segmental glomerulosclerosis (FSGS) is a proteinuric kidney disease caused by breakdown of the glomerular filtration barrier in the kidney.Podocytes are a key cellular component of the glomerular filtration barrier; efficient barrier function requires dynamic regulation of the podocyte actin-based cytoskeleton.In this issue (4127-4137), Akilesh and colleagues report human genetic and cell biological data that support the idea that disruption of the podocyte cytoskeleton contributes to the development of FSGS.Initial analysis indicated that expression of the actin regulatory protein Rho GTPase-activating protein 24 (Arhgap24) was upregulated in mouse podocytes as they differentiated.Increased Arhgap24 levels were associated with a decrease in membrane ruffling and cell motility, which are likely important for podocyte maintenance of glomerular filtration barrier integrity.These data have clinical relevance, since further analysis identified a mutation in the ARHGAP24 gene in affected members of a family with FSGS.The mutation impaired the Rac1 GTPase-activating protein activity of Arhgap24, leading the authors to suggest that modulating Arhgap24 activity could provide a new way to treat FSGS.
MEDICAL INFLUENCE AND JAPAN'S DEVELOPMENT.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dynein Light Chain 1, a p21-Activated Kinase 1-Interacting Substrate, Promotes Cancerous Phenotypes
Authors: Ratna K. Vadlamudi, Rozita Bagheri-Yarmand, Zhibo Yang, Seetharaman Balasenthil, Diep Nguyen, Aysegul Sahin, Petra den Hollander, Rakesh Kumar
Journal: Cancer Cell (2013)
Sigmoidoscopic screening in the 1990s
Authors: D. F. Ransohoff
Journal: JAMA (1993)

COLORECTAL cancer (CRC) is a major cause of morbidity and mortality, accounting for 140000 new cases and 60 000 deaths per year in the United States.<sup>1</sup>At present, the most promising strategy to reduce this burden is some form of periodic screening. The goal of screening is early detection of surgically curable cancers, as well as their likely precursors, adenomatous polyps; both may be present for years before disseminated, incurable cancer develops. Sigmoidoscopic screening at intervals of 3 to 5 years has been widely recommended<sup>2-5</sup>because sigmoidoscopy has high sensitivity for detecting early cancers and adenomas. However, routine sigmoidoscopic screening is controversial<sup>6-8</sup>because there is no direct evidence from a ramdomized controlled trial to show that screening reduces CRC mortality. Also, the effort involved in applying sigmoidoscopic screening is very large. Thus, despite long-standing recommendations, sigmoidoscopic screening is performed in less than 5% to 10% of eligible